{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T06:10:04Z","timestamp":1720591804042},"reference-count":26,"publisher":"Japanese Society of Internal Medicine","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2019,2,15]]},"DOI":"10.2169\/internalmedicine.1686-18","type":"journal-article","created":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T22:24:56Z","timestamp":1536704696000},"page":"575-580","source":"Crossref","is-referenced-by-count":1,"title":["Gemcitabine, Dexamethasone, and Cisplatin Regimen as an Effective Salvage Therapy for High-grade B-cell Lymphoma with &lt;i&gt;MYC&lt;\/i&gt; and &lt;i&gt;BCL2&lt;\/i&gt; and\/or &lt;i&gt;BCL6&lt;\/i&gt; Rearrangements"],"prefix":"10.2169","volume":"58","author":[{"given":"Masaki","family":"Mitobe","sequence":"first","affiliation":[{"name":"Department of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Kawamoto","sequence":"additional","affiliation":[{"name":"Department of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaharu","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maiko","family":"Kiryu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suguru","family":"Tamura","sequence":"additional","affiliation":[{"name":"Department of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayako","family":"Nanba","sequence":"additional","affiliation":[{"name":"Department of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Suwabe","sequence":"additional","affiliation":[{"name":"Department of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoko","family":"Fuse","sequence":"additional","affiliation":[{"name":"Department of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiko","family":"Shibasaki","sequence":"additional","affiliation":[{"name":"Department of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayoshi","family":"Masuko","sequence":"additional","affiliation":[{"name":"Department of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Miyoshi","sequence":"additional","affiliation":[{"name":"Department of Pathology, School of Medicine, Kurume University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Ohshima","sequence":"additional","affiliation":[{"name":"Department of Pathology, School of Medicine, Kurume University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirohito","family":"Sone","sequence":"additional","affiliation":[{"name":"Department of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Takizawa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"1. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127: 2375-2390, 2016.","journal-title":"Blood","ISSN":"http:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Staton AD, Cohen JB. A clinician&apos;s approach to double-hit lymphoma: identification, evaluation, and management. J Oncol Pract 12: 232-238, 2016.","DOI":"10.1200\/JOP.2015.009647"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Johnson NA, Savage KJ, Ludkovski O, et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood 114: 2273-2279, 2009.","DOI":"10.1182\/blood-2009-03-212191"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Savage KJ, Johnson NA, Ben-Neriah S, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 114: 3533-3537, 2009.","DOI":"10.1182\/blood-2009-05-220095"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Kawamoto K, Miyoshi H, Yoshida N, et al. MYC translocation and\/or BCL 2 protein expression are associated with poor prognosis in diffuse large B-cell lymphoma. Cancer Sci 107: 853-861, 2016.","DOI":"10.1111\/cas.12942"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Tomita N, Tokunaka M, Nakamura N, et al. Clinicopathological features of lymphoma\/leukemia patients carrying both BCL2 and MYC translocations. Haematologica 94: 935-943, 2009.","DOI":"10.3324\/haematol.2008.005355"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Chen AI, Leonard JT, Okada CY, et al. Outcomes of DA-EPOCH-R induction plus autologous transplant consolidation for double hit lymphoma. Leuk Lymphoma 1-6, 2017.","DOI":"10.1080\/10428194.2017.1406085"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin&apos;s lymphoma. N Engl J Med 333: 1540-1545, 1995.","DOI":"10.1056\/NEJM199512073332305"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 28: 4184-4190, 2010.","DOI":"10.1200\/JCO.2010.28.1618"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Friedberg JW. Relapsed\/refractory diffuse large B-cell lymphoma. Hematology \/ the Education Program of the American Society of Hematology American Society of Hematology Education Program 2011: 498-505, 2011.","DOI":"10.1182\/asheducation-2011.1.498"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Mey UJ, Orlopp KS, Flieger D, et al. Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin&apos;s lymphoma. Cancer Invest 24: 593-600, 2006.","DOI":"10.1080\/07357900600814490"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Martin A, Caballero MD; Grupo Espanol de Linfomas\/Trasplante Autologo de Medula O. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: influence of prior autologous stem-cell transplantation on outcome. Haematologica 94: 744, 2009.","DOI":"10.3324\/haematol.2009.006452"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Kewalramani T, Zelenetz AD, Nimer SD, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 103: 3684-3688, 2004.","DOI":"10.1182\/blood-2003-11-3911"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Oki Y, Ogura M, Kato H, et al. Phase II study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cell non-Hodgkin&apos;s lymphoma. Cancer Sci 99: 179-184, 2008.","DOI":"10.1111\/j.1349-7006.2007.00662.x"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Jermann M, Jost LM, Taverna C, et al. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study. Ann Oncol 15: 511-516, 2004.","DOI":"10.1093\/annonc\/mdh093"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Rodriguez MA, Cabanillas FC, Hagemeister FB, et al. A phase II trial of mesna\/ifosfamide, mitoxantrone and etoposide for refractory lymphomas. Ann Oncol 6: 609-611, 1995.","DOI":"10.1093\/oxfordjournals.annonc.a059252"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. Crump M, Baetz T, Couban S, et al. Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Cancer 101: 1835-1842, 2004.","DOI":"10.1002\/cncr.20587"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Kuruvilla J, Keating A, Crump M. How I treat relapsed and refractory Hodgkin lymphoma. Blood 117: 4208-4217, 2011.","DOI":"10.1182\/blood-2010-09-288373"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Rosenthal A, Younes A. High grade B-cell lymphoma with rearrangements of MYC and BCL2 and\/or BCL6: Double hit and triple hit lymphomas and double expressing lymphoma. Blood Rev 31: 37-42, 2017.","DOI":"10.1016\/j.blre.2016.09.004"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Petrich AM, Gandhi M, Jovanovic B, et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood 124: 2354-2361, 2014.","DOI":"10.1182\/blood-2014-05-578963"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Oki Y, Noorani M, Lin P, et al. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol 166: 891-901, 2014.","DOI":"10.1111\/bjh.12982"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Sun H, Savage KJ, Karsan A, et al. Outcome of patients with non-Hodgkin lymphomas with concurrent MYC and BCL2 rearrangements treated with CODOX-M\/IVAC with rituximab followed by hematopoietic stem cell transplantation. Clin Lymphoma Myeloma Leuk 15: 341-348, 2015.","DOI":"10.1016\/j.clml.2014.12.015"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Moccia AA, Hitz F, Hoskins P, et al. Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed\/refractory diffuse large B-cell lymphoma and Hodgkin lymphoma. Leuk Lymphoma 58: 324-332, 2017.","DOI":"10.1080\/10428194.2016.1193852"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Wang JJ, Dong M, He XH, et al. GDP (gemcitabine, dexamethasone, and cisplatin) is highly effective and well-tolerated for newly diagnosed stage IV and relapsed\/refractory extranodal natural killer\/T-cell lymphoma, Nasal Type. Medicine 95: e2787, 2016.","DOI":"10.1097\/MD.0000000000002787"},{"key":"25","unstructured":"25. Ramzi M, Rezvani A, Dehghani M. GDP versus ESHAP regimen in relapsed and\/or refractory Hodgkin lymphoma: a comparison study. Int J Hematol Oncol Stem Cell Res 9: 10-14, 2015."},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Miyoshi H, Arakawa F, Sato K, et al. Comparison of CD20 expression in B-cell lymphoma between newly diagnosed, untreated cases and those after rituximab treatment. Cancer Sci 103: 1567-1573, 2012.","DOI":"10.1111\/j.1349-7006.2012.02307.x"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/4\/58_1686-18\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T05:50:40Z","timestamp":1720590640000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/4\/58_1686-18\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,15]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.1686-18","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,15]]}}}